Versant Ventures

Versant Ventures, established in 1999, is a global healthcare investment firm headquartered in San Francisco, California. With over $2.3 billion under management and offices in North America and Europe, the firm invests across the healthcare sector, with a focus on discovering and developing novel therapeutics. Versant's team, comprising deep investment, operating, and scientific expertise, takes a hands-on approach to company building. Since inception, over 65 Versant companies have achieved successful acquisitions or IPOs.

Mehmet Badur

Principal

Bradley Bolzon

Managing Director

Jeremy Caldwell

Venture Partner

Jerel Davis Ph.D

Managing Director

Rich Van Doren

CFO

Joel Drewry

Principal

Gianni Gromo

Partner

Katharina Kreymborg Ph.D

Principal

William Link

Co-Founder

Guido Magni

Partner

Shane Mulligan

Principal

Kirk G. Nielsen

Managing Partner

Clare Ozawa

Managing Director

Nikita Sharma

Principal

Charles Warden

Managing Director

Rami Hannoush Ph.D

Venture Partner

Past deals in Medical

Granite Bio

Series A in 2025
Granite Bio is a biotechnology company focused on developing novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company specializes in creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological processes associated with these diseases. By concentrating on these advanced treatments, Granite Bio contributes to the broader fields of biotechnology, pharmaceuticals, and diagnostics, ultimately seeking to improve patient outcomes in complex medical conditions.

Light Horse Therapeutics

Series A in 2025
Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of novel therapies.

858 Therapeutics

Series B in 2024
858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

Borealis Biosciences

Series A in 2024
Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based medicines specifically for kidney diseases. The company utilizes its expertise in molecular and cellular biology, chemistry, and analytical capabilities to identify target opportunities within different patient subsets affected by kidney conditions. By refining methods for delivering RNA medicines to specific cell types, Borealis Biosciences aims to tackle significant unmet medical needs in the treatment of kidney diseases.

Jade Biosciences

Series A in 2024
Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

Bright Peak Therapeutics

Series C in 2024
Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

SixPeaks Bio

Series A in 2024
SixPeaks Bio focuses on developing innovative therapies aimed at promoting healthy weight loss for individuals struggling with obesity. The company is working on a pipeline of medicines that utilize dual-specific antibodies to target activin type IIA and B receptors. This approach aims to help patients achieve weight loss while preserving skeletal muscle mass, addressing a common concern associated with traditional weight-loss methods that often lead to muscle loss alongside fat reduction. Through its research and development efforts, SixPeaks Bio seeks to provide effective solutions for sustainable weight management and improved health outcomes.

LENZ Therapeutics

Post in 2024
LENZ Therapeutics is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapies. It focuses on addressing vision-related issues, particularly presbyopia, which affects the near vision of individuals, especially those over the age of 45. The company's primary product is an aceclidine-based eye drop designed to restore near vision loss associated with this condition. Through its advancements in ophthalmic pharmaceuticals, LENZ Therapeutics aims to improve the quality of life for those impacted by vision challenges.

FireFly Bio

Series A in 2024
FireFly Bio focuses on developing Degrader Antibody Conjugates (DACs), a novel approach that merges the benefits of antibody-drug conjugates with selective protein degraders. This proprietary healthcare platform is designed to enhance cancer treatment by ensuring the precise delivery of therapeutic agents to targeted tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create more effective and targeted medicines that improve patient outcomes in the fight against cancer.

Nouscom

Series C in 2023
Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Nexo Therapeutics

Series A in 2023
Nexo Therapeutics is a biotechnology company focused on developing small-molecule therapies for cancer patients who have few effective treatment options. The company utilizes a specialized platform that integrates covalent ligand discovery with chemical biology to create innovative oncology drugs aimed at challenging targets that have been difficult to address in the past. By advancing its pipeline of novel therapies, Nexo Therapeutics seeks to provide new avenues for treatment, ultimately enhancing the care available to individuals battling cancer and other related diseases.

Kate Therapeutics

Series A in 2023
Kate Therapeutics is a biotechnology company dedicated to developing adeno-associated virus (AAV)-based gene therapies for genetically defined muscle and heart diseases. The company employs advanced technology platforms to enhance tissue-specific delivery and gene regulation, overcoming significant challenges associated with current gene therapies. By utilizing innovative capsids, Kate Therapeutics achieves superior muscle transduction and effectively de-targets the liver, allowing for more efficient tissue transduction at lower viral doses. This approach addresses key limitations in muscle gene delivery, aiming to improve treatment outcomes for patients with muscle and heart conditions.

Santa Ana Bio

Series A in 2023
Santa Ana Bio is a biotechnology company focused on developing precision therapies for autoimmune and inflammatory diseases. By utilizing advanced technologies such as deep cell profiling, single-cell genomics, and multi-omics platforms, the company designs targeted biologics that aim to provide effective and personalized treatment options. Through its innovative approach, Santa Ana Bio seeks to enhance patient outcomes and improve quality of life for those affected by autoimmune conditions.

Belharra Therapeutics

Series A in 2023
Belharra Therapeutics is a privately held drug discovery company based in the San Francisco Bay Area, primarily operating out of San Diego. The company utilizes a novel photoaffinity-based chemoproteomics platform that allows its scientists to identify small molecule drug candidates for any binding site on any protein, in various conformational states, and across different cell types. By integrating innovative biology, medicinal chemistry, and bioinformatics, Belharra aims to discover transformative, first-in-class medicines targeting serious diseases and conditions. Through its advanced drug discovery approach, the company seeks to revolutionize the identification of novel therapeutic starting points, ultimately benefiting patients in need of effective treatments.

Cimeio Therapeutics

Series A in 2022
Cimeio Therapeutics develops curative treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders. The technology platform developed by Cimeio is based on the design and expression of modified variants of naturally occurring cell surface proteins in HSCs. The SCIP platform could allow more patients facing debilitating and fatal diseases to receive a life-saving HSC transplant. Its mission is to significantly improve the eligibility and outcomes of hematopoietic stem cell transplants and adoptive cell therapy.

Coda Biotherapeutics

Venture Round in 2021
Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

SanReno Therapeutics

Funding Round in 2021
SanReno Therapeutics specializes in the development, manufacturing, and commercialization of therapies for kidney diseases in several regions including the People's Republic of China, Hong Kong, Macau, Taiwan, and Singapore. Established through a joint venture involving Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, the company is dedicated to researching and producing innovative biotech solutions aimed at improving the quality of life for patients suffering from kidney-related conditions.

858 Therapeutics

Series A in 2021
858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

T-knife

Series B in 2021
T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Turnstone Biologics

Series D in 2021
Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

LENZ Therapeutics

Series A in 2021
LENZ Therapeutics is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative ophthalmic therapies. It focuses on addressing vision-related issues, particularly presbyopia, which affects the near vision of individuals, especially those over the age of 45. The company's primary product is an aceclidine-based eye drop designed to restore near vision loss associated with this condition. Through its advancements in ophthalmic pharmaceuticals, LENZ Therapeutics aims to improve the quality of life for those impacted by vision challenges.

RayzeBio

Series C in 2021
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Bright Peak Therapeutics

Series B in 2021
Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

Graphite Bio

Series B in 2021
Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that specializes in targeted DNA integration to develop innovative therapies for severe diseases. The company utilizes a precision gene editing approach to precisely correct genetic mutations, replace malfunctioning genes, and insert therapeutic genetic sequences at specific locations within the genome. Its technology aims to transform treatment paradigms by enabling the targeted integration of genetic payloads, which could potentially cure a range of serious and life-threatening conditions. Graphite Bio was formerly known as Integral Medicines, Inc. before rebranding in August 2020, and it was incorporated in 2019.

Pipeline Therapeutics

Series C in 2021
Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

Gritstone bio

Post in 2020
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

RayzeBio

Series B in 2020
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

RayzeBio

Series A in 2020
RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Graphite Bio

Series A in 2020
Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that specializes in targeted DNA integration to develop innovative therapies for severe diseases. The company utilizes a precision gene editing approach to precisely correct genetic mutations, replace malfunctioning genes, and insert therapeutic genetic sequences at specific locations within the genome. Its technology aims to transform treatment paradigms by enabling the targeted integration of genetic payloads, which could potentially cure a range of serious and life-threatening conditions. Graphite Bio was formerly known as Integral Medicines, Inc. before rebranding in August 2020, and it was incorporated in 2019.

Chinook Therapeutics

Post in 2020
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently prepared for Phase III trials targeting IgA nephropathy and other primary glomerular diseases. In addition to atrasentan, Chinook is developing BION-1301, an investigational anti-APRIL monoclonal antibody evaluated in a Phase Ib trial for IgA nephropathy, and CHK-336, a preclinical candidate aimed at treating an undisclosed ultra-orphan kidney disease. Chinook Therapeutics is also engaged in research programs addressing other rare and severe chronic kidney conditions, including polycystic kidney disease.

T-knife

Series A in 2020
T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Matterhorn Biosciences

Venture Round in 2020
Matterhorn Biosciences is a biotechnology company dedicated to developing cellular therapies that target the MR1 molecule, which displays cancer-specific metabolites on the surface of cancer cells. The company's approach involves creating M-TCR cell therapies that utilize T cells designed to recognize and attack these metabolites, facilitating the destruction of tumors across various tissue types. By leveraging a library of T-cell receptors that can be linked to MR1-specific T cells, Matterhorn aims to enhance the ability of the immune system to identify and eliminate a wide range of cancerous cells. This innovative focus positions Matterhorn at the forefront of cancer treatment research, aiming to provide effective therapeutic options for patients facing challenging diagnoses.

Bright Peak Therapeutics

Series A in 2020
Bright Peak Therapeutics is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company specializes in cytokine therapeutics that enable tissue and cell-specific targeting of cytokine payloads. This approach aims to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging innovative immuno-cytokines, Bright Peak seeks to provide more effective therapeutic options for complex medical conditions.

Pandion Therapeutics

Series B in 2020
Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Pipeline Therapeutics

Series B in 2019
Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

Coda Biotherapeutics

Series A in 2019
Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Anokion

Series B in 2019
Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative immunotherapy aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology can be applied across a wide range of clinical indications, targeting both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens for precise therapy, Anokion aims to provide effective treatment options that minimize side effects, thereby improving patient outcomes in the management of autoimmune and allergic diseases.

Passage Bio

Series B in 2019
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Repare Therapeutics

Series B in 2019
Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

Chinook Therapeutics

Series A in 2019
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently prepared for Phase III trials targeting IgA nephropathy and other primary glomerular diseases. In addition to atrasentan, Chinook is developing BION-1301, an investigational anti-APRIL monoclonal antibody evaluated in a Phase Ib trial for IgA nephropathy, and CHK-336, a preclinical candidate aimed at treating an undisclosed ultra-orphan kidney disease. Chinook Therapeutics is also engaged in research programs addressing other rare and severe chronic kidney conditions, including polycystic kidney disease.

Oyster Point

Series B in 2019
Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Passage Bio

Series A in 2019
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Akero Therapeutics

Series B in 2018
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Gotham Therapeutics

Series A in 2018
Gotham Therapeutics is a biotechnology company based in New York that focuses on developing a novel class of drugs targeting epitranscriptomics machinery. Founded in 2017, the company aims to provide new treatment options for patients with cancers, autoimmune disorders, and neurodegenerative diseases. Its approach involves creating small molecules that modify the activity of messenger ribonucleic acid (mRNA) to influence protein transcription. This innovative strategy allows Gotham Therapeutics to potentially optimize therapeutic outcomes for individuals suffering from serious health conditions.

Coda Biotherapeutics

Series A in 2018
Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

AlterG

Venture Round in 2018
AlterG, Inc. is a manufacturer and distributor of rehabilitation and therapy equipment, headquartered in Fremont, California. The company specializes in developing innovative devices, most notably the Anti-Gravity Treadmill, which utilizes pressure-unweighting technology to facilitate physical therapy for individuals recovering from lower extremity injuries or surgeries. AlterG also offers the Stride Smart Gait Analytics treadmill, designed to enhance the benefits of anti-gravity therapy, and the AlterG Digital Video Monitoring System, which fosters collaboration between patients and therapists to optimize rehabilitation outcomes. Additionally, the company provides various accessories such as standard and performance shorts, as well as mats, to complement its rehabilitation equipment. Founded in 2004, AlterG aims to empower individuals to achieve their physical goals by improving mobility, reducing pain, and accelerating recovery times.

Akero Therapeutics

Series A in 2018
Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Inari Medical

Series C in 2018
Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.

Pandion Therapeutics

Series A in 2018
Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Metavention

Series C in 2018
Metavention, Inc., incorporated in 2012 and based in Dover, Delaware, focuses on innovative treatments aimed at addressing metabolic diseases linked to overactive sympathetic nerves. The company has developed a renal denervation procedure utilizing its IRF denervation system, which applies radio frequency energy to specifically target these nerves. This approach is designed to provide a permanent solution for conditions such as high blood pressure and complications associated with Type 2 diabetes, including elevated glucose levels and abnormal liver function. By employing trans-catheter devices that leverage standard interventional vascular techniques, Metavention equips medical practitioners with effective tools for diagnosing and treating patients suffering from these metabolic disorders.

Oyster Point

Series A in 2017
Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Nouscom

Series B in 2017
Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Gritstone bio

Series B in 2017
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

Venatorx Pharmaceuticals

Series B in 2017
Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Repare Therapeutics

Series A in 2017
Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, specializing in the discovery and development of novel therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which combines genome-wide and CRISPR-enabled technology, the company systematically identifies targeted cancer therapies addressing genomic instability, particularly in DNA damage repair. Its lead candidate, RP-3500, is an oral small molecule inhibitor designed to treat solid tumors with specific DNA damage repair-related genomic alterations. Additionally, Repare is advancing a CCNE1-SL inhibitor program targeting tumors with CCNE1 amplification, along with a Polymerase Theta program focused on BRCA mutations and related genomic alterations. Founded in 2016, the company aims to improve cancer treatment by leveraging innovative drug discovery methods and addressing the unique vulnerabilities of tumor cells.

Monteris Medical

Series C in 2017
Monteris Medical, Inc. is a medical device company that specializes in developing and marketing technologies for minimally invasive neurosurgery, particularly focused on the treatment of brain lesions. The company's flagship product, the NeuroBlate System, is a laser thermotherapy system designed for the volumetric ablation of pathological brain lesions, including both primary and metastatic tumors. This system utilizes magnetic resonance imaging (MRI) guidance and applies focused laser energy to effectively target and ablate tumors while minimizing damage to surrounding healthy tissue. Monteris Medical also offers various stereotactic anchoring devices for precise image-guided trajectory alignment, as well as stabilization systems for MRI-based procedures that require head fixation. Founded in 1999 and headquartered in Plymouth, Minnesota, the company serves neurosurgeons across the United States through a dedicated sales force. Monteris Medical was previously known as AutoLITT until rebranding in 2003.

Tarveda Therapeutics

Series D in 2017
Tarveda Therapeutics is focused on developing innovative cancer therapies specifically for solid tumors. The company specializes in miniature drug conjugates, with its lead candidate, PEN-866, targeting activated Heat Shock Protein 90 (HSP90) to deliver a potent topoisomerase 1 inhibitor, SN38, directly to tumor cells. Additionally, Tarveda is advancing another drug conjugate aimed at treating patients with neuroendocrine tumors and small cell lung cancer that express somatostatin receptor 2 (SSTR2). By leveraging its targeted drug delivery platform, Tarveda Therapeutics aims to improve treatment outcomes for patients with difficult-to-treat cancers while reducing potential side effects. Founded in 2011 and based in Watertown, Massachusetts, the company was previously known as Blend Therapeutics until its rebranding in 2016.

Jecure Therapeutics

Series A in 2017
Jecure Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small-molecule therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Established in 2015 and operating as a subsidiary of Genentech, Inc. since 2018, the company specializes in innovative drug discovery programs aimed at addressing serious inflammatory diseases. Jecure's therapeutics work by blocking inflammasome activation and disrupting the inflammation processes that lead to liver cell injury and death. The company utilizes advanced methodologies, including SiRNA-based murine fibrosis models for target identification and validation, as well as unique in-vivo screening models that replicate key features of NASH. This approach enables the identification of drug candidates capable of intervening throughout the disease progression, facilitating a clearer path for translational development.

Turnstone Biologics

Series B in 2016
Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Rox Medical

Series E in 2016
ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

Nouscom

Series A in 2016
Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Kyras Therapeutics

Series A in 2015
Kyras Therapeutics Inc. is a biotechnology company based in New York, specializing in the development of drugs aimed at treating incurable cancers and developmental disorders. Founded in 2015, the company focuses on addressing conditions linked to mutations in RAS genes, which are responsible for a significant percentage of various cancers, including pancreatic, colorectal, and lung cancers. By targeting these mutations, Kyras Therapeutics aims to provide effective treatments that can potentially cure patients suffering from these challenging health issues.

Inception IBD

Series A in 2015
Inception IBD is focused on translating academic discoveries in the field of IBD

Turnstone Biologics

Series A in 2015
Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Gritstone bio

Series A in 2015
Gritstone bio is a biotechnology company focused on developing personalized immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surfaces of infected cells. This approach leverages the immune system's ability to recognize abnormal cell targets, which is crucial for both anti-tumor and anti-viral immunity. Gritstone bio is building a robust pipeline of immunotherapy product candidates, including GRANITE, SLATE, and CORAL, designed to address various solid tumors. Through these developments, Gritstone bio aims to contribute to the evolving landscape of cancer treatment and enhance patient outcomes.

Audentes Therapeutics

Series C in 2015
Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

GenSight Biologics

Series B in 2015
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Piqur Therapeutics

Series A in 2015
PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, specializing in the discovery and development of innovative anti-cancer drugs. Founded in 2011, the company focuses on therapies that target lipid kinase (PI3K) and mTOR, both of which are established drug targets in oncology. PIQUR has developed a robust pipeline of compounds, including its lead product, bimiralisib, which aims for dual inhibition of the PI3K/mTOR pathway. The company's mission is to create breakthrough targeted medicines for oncology and dermatology, addressing the treatment of various cancers and genetic diseases. With a secured patent portfolio protecting many of its chemical compounds, PIQUR Therapeutics is dedicated to enhancing the quality of life for cancer patients through advanced therapeutic options.

Inari Medical

Series B in 2015
Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.

NeuWave Medical

Series C in 2015
NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Laguna Pharmaceuticals

Series B in 2015
Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and marketing small molecule pharmaceuticals, particularly vanoxerine, which is a therapeutic candidate for treating atrial fibrillation and atrial flutter. Originally founded in 2006 as ChanRx Corp., the company rebranded to Laguna Pharmaceuticals in February 2015. Headquartered in La Jolla, California, Laguna Pharmaceuticals aims to address the medical needs associated with atrial fibrillation, a prevalent arrhythmia linked to serious cardiovascular events such as heart attacks and strokes.

Audentes Therapeutics

Series B in 2014
Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

AcuFocus

Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.

Ceterix Orthopaedics

Series B in 2014
Ceterix Orthopaedics, Inc. is a medical technology company focused on developing innovative surgical tools for arthroscopic procedures. Based in Fremont, California, the company offers the Ceterix NovoStitch® Plus Meniscal Repair System, designed to repair various complex meniscal tears, including horizontal, radial, and root tears. Additionally, Ceterix provides the Novocut Suture Manager, a device that facilitates suture management during surgeries. The company's technology allows orthopedic surgeons to non-invasively create intricate suture patterns in tight joint compartments while safeguarding surrounding structures such as nerves and cartilage. Founded in 2010 by Dr. Justin Saliman, an orthopedic surgeon specializing in sports medicine, Ceterix aims to enhance the outcomes of arthroscopic procedures, addressing issues that often lead to untreated tears or the more invasive meniscectomy. As of January 2019, Ceterix operates as a subsidiary of Smith & Nephew plc.

Anokion

Series A in 2014
Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative immunotherapy aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology can be applied across a wide range of clinical indications, targeting both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens for precise therapy, Anokion aims to provide effective treatment options that minimize side effects, thereby improving patient outcomes in the management of autoimmune and allergic diseases.

ForSight Labs

Series C in 2014
ForSight Labs is dedicated to developing innovative ophthalmic technologies aimed at enhancing the sight and quality of life for visually impaired patients. The organization collaborates with entrepreneurs, investors, and clinicians to drive advancements in eye care through the creation and commercialization of high-impact solutions. With millions of individuals in the U.S. suffering from vision impairment and the associated economic burden exceeding $50 billion annually, ForSight Labs addresses a significant public health challenge. Their focus includes developing treatments for conditions such as glaucoma, which can lead to irreversible blindness in adults. By fostering a creative and cooperative environment, ForSight Labs strives to deliver effective solutions to the ophthalmic community and the patients it serves.

ForSight VISION5

Series C in 2014
ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in developing innovative drug delivery technologies aimed at treating various eye conditions. The company focuses on creating non-invasive products designed to replace traditional eye drops, offering sustained therapy for significant eye diseases such as glaucoma, dry eye, and allergies. Currently, ForSight VISION5 is in its second Phase 2 clinical study for its lead product, the Helios insert, which represents a significant advancement in ocular treatment options.

AAVLife

Series A in 2014
AAVLife is a gene therapy company based in Paris, France, founded in 2014. The company focuses on developing therapies for Friedreich's Ataxia Cardiomyopathy, a genetic disorder that leads to severe neurological and cardiac symptoms. AAVLife's innovative approach utilizes an adeno-associated virus to deliver a normal gene into cardiac tissue, which has shown promise in restoring cardiac function and reversing heart enlargement in preclinical models. The company has made significant progress in its research to determine optimal dosing and administration routes for upcoming clinical trials. AAVLife aims to engage with regulatory authorities to finalize the design of these trials, with plans to initiate an observational study and a Phase I/II clinical trial. Through its efforts, AAVLife is committed to advancing gene therapy solutions for patients affected by this life-threatening condition, emphasizing its dedication to patient communities and the organizations that support them.

Sequent Medical

Series D in 2014
Sequent Medical, Inc. is a medical device company focused on developing catheter-based neurovascular technologies. Founded in 2007 and headquartered in Aliso Viejo, California, with operations in Bonn, Germany, the company has created the proprietary Microbraid technology, which is integral to its WEB Aneurysm Embolization System. This system provides a versatile option for treating both ruptured and unruptured intracranial aneurysms and has received CE mark approval. The WEB device has been successfully used to treat nearly 600 aneurysms across Europe, Latin America, and New Zealand, although it is not available for sale or use in the United States. Sequent Medical, Inc. operates as a subsidiary of MicroVention, Inc.

Piqur Therapeutics

Series A in 2014
PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, specializing in the discovery and development of innovative anti-cancer drugs. Founded in 2011, the company focuses on therapies that target lipid kinase (PI3K) and mTOR, both of which are established drug targets in oncology. PIQUR has developed a robust pipeline of compounds, including its lead product, bimiralisib, which aims for dual inhibition of the PI3K/mTOR pathway. The company's mission is to create breakthrough targeted medicines for oncology and dermatology, addressing the treatment of various cancers and genetic diseases. With a secured patent portfolio protecting many of its chemical compounds, PIQUR Therapeutics is dedicated to enhancing the quality of life for cancer patients through advanced therapeutic options.

Inception Sciences

Series A in 2013
Inception Sciences, Inc. is a drug discovery company established in 2011, located in San Diego, California, with additional research facilities in Vancouver and Saint Laurent, Canada. The company specializes in developing small molecule therapies aimed at addressing diseases and disorders that have significant unmet medical needs. By collaborating with academic experts, Inception Sciences translates biological insights into innovative and targeted drug candidates. The team boasts a strong history in drug discovery, having contributed to the development of clinical-stage compounds for conditions such as fibrosis, asthma, and chronic obstructive pulmonary disease (COPD) while previously working with notable pharmaceutical firms.

Immune Design

Series C in 2013
Immune Design Corp. is a clinical-stage immunotherapy company headquartered in Seattle, Washington, that specializes in developing innovative treatments for cancer through in vivo methods that empower the immune system to combat disease. The company utilizes its ZVex and GLAAS discovery platforms to create a new generation of immune-based products. Its primary product candidate, G100, is currently undergoing Phase II clinical trials for follicular non-Hodgkin lymphoma, while another candidate, CMB305, focuses on enhancing tumor-specific cytotoxic T cells. Immune Design's research aims to overcome limitations of existing oncological therapies, and the company has established collaboration and license agreements with Sanofi Pasteur. Founded in 2008, Immune Design operates as a subsidiary of Merck & Co., Inc.

Inari Medical

Series A in 2013
Inari Medical, Inc. is a commercial-stage medical device company based in Irvine, California, that specializes in developing innovative products for the treatment of venous diseases. Founded in 2011, the company's primary focus is on venous thromboembolism, which it addresses through two key devices: the ClotTriever and the FlowTriever. The ClotTriever is designed for the minimally invasive removal of blood clots from peripheral blood vessels, specifically targeting patients with deep vein thrombosis. Meanwhile, the FlowTriever system effectively treats pulmonary embolism by removing large clots from major blood vessels without the need for thrombolytic drugs. Inari Medical primarily generates its revenue from the United States while also reaching international markets.

Audentes Therapeutics

Series A in 2013
Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Veracyte

Series C in 2013
Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.

ForSight Labs

Series B in 2013
ForSight Labs is dedicated to developing innovative ophthalmic technologies aimed at enhancing the sight and quality of life for visually impaired patients. The organization collaborates with entrepreneurs, investors, and clinicians to drive advancements in eye care through the creation and commercialization of high-impact solutions. With millions of individuals in the U.S. suffering from vision impairment and the associated economic burden exceeding $50 billion annually, ForSight Labs addresses a significant public health challenge. Their focus includes developing treatments for conditions such as glaucoma, which can lead to irreversible blindness in adults. By fostering a creative and cooperative environment, ForSight Labs strives to deliver effective solutions to the ophthalmic community and the patients it serves.

Ocular Therapeutix

Series D in 2013
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for eye diseases using its proprietary bioresorbable hydrogel platform technology. The company offers several products, including ReSure Sealant, a hydrogel ophthalmic wound sealant designed to protect corneal incisions after cataract surgery, and DEXTENZA, an ophthalmic insert for the treatment of post-surgical ocular pain and inflammation, as well as allergic conjunctivitis and dry eye diseases. Ocular Therapeutix is also developing OTX-TP, an insert aimed at reducing intraocular pressure in glaucoma patients, and OTX-TIC, an intracameral implant for similar indications, along with OTX-TKI, an intravitreal implant targeting wet age-related macular degeneration. In addition, the company has preclinical programs focused on various ocular conditions. Ocular Therapeutix collaborates with Regeneron Pharmaceuticals to integrate its hydrogel technology with Regeneron's VEGF-targeting compounds for retinal disease treatments. Founded in 2006, the company is headquartered in Bedford, Massachusetts.

GenSight Biologics

Series A in 2013
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Novira Therapeutics

Series A in 2013
Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

Achaogen

Series D in 2013
Achaogen, Inc. is a biopharmaceutical company focused on developing antibacterial agents to combat multi-drug resistant (MDR) gram-negative infections. The company's primary product, plazomicin, is designed to treat serious bacterial infections caused by MDR enterobacteriaceae, particularly carbapenem-resistant strains. Additionally, Achaogen is working on C-Scape, an orally-administered combination therapy targeting infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. Achaogen has established several collaboration agreements, including partnerships with Thermo Fisher Scientific for assay development, and Ionis Pharmaceuticals for the advancement of aminoglycoside antibacterial compounds. The company generates revenue primarily through government contracts for research and development. Founded in 2002 and based in South San Francisco, California, Achaogen filed for Chapter 11 bankruptcy in April 2019, transitioning to a liquidation plan in May 2020.

Glaukos

Series F in 2013
Glaukos Corporation is an ophthalmic medical technology company dedicated to developing innovative products and procedures aimed at transforming the treatment of glaucoma, a major cause of blindness worldwide. The company has pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance traditional glaucoma management approaches. Its flagship product, the iStent, was introduced in the United States in 2012 and is designed as a micro-bypass stent that can be inserted during cataract surgery to lower intraocular pressure in adults with mild-to-moderate open-angle glaucoma. Glaukos is also advancing its product pipeline with the iStent SA, a two-stent system that utilizes a unique auto-injection inserter for standalone procedures. Founded in 1998 and headquartered in San Clemente, California, Glaukos aims to build a comprehensive portfolio of injectable micro-scale therapies to address various glaucoma disease states and progression.

Glumetrics

Debt Financing in 2013
GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Minerva Surgical

Venture Round in 2012
Minerva Surgical Inc. is a medical technology company based in Redwood City, California, dedicated to women's healthcare. Founded in 2008, the company specializes in developing, manufacturing, and commercializing minimally invasive solutions for uterine health. Its flagship product, the Minerva Endometrial Ablation System, is designed to treat abnormal uterine bleeding, a common issue affecting many women. Minerva Surgical offers a comprehensive range of alternatives to hysterectomy, aiming to address the underlying causes of abnormal uterine bleeding while preserving the uterus. These solutions are applicable in various medical environments and seek to overcome the limitations of traditional treatment methods, providing women with effective and less invasive options for their healthcare needs.

CardiAQ Valve Technologies

Series B in 2012
CardiAQ Valve Technologies is a privately held company specializing in advanced solutions for heart valve replacement, with a primary focus on transcatheter mitral valve implantation (TMVI). The company has developed a system that allows physicians to implant a mitral valve within a beating heart, thereby eliminating the need for open-heart surgery. This innovative approach aims to enhance patient outcomes and simplify the procedure for both patients and healthcare providers.

Cerephex

Series A in 2012
Cerephex Corporation develops non-invasive treatment and diagnostic technologies for chronic centralized pain conditions, specifically focusing on fibromyalgia. The company's flagship product, NeuroPoint, is a point-of-care medical device utilizing proprietary RINCE technology, which employs noninvasive cortical electrostimulation to target and modulate brain function. This device aims to address the abnormal pain processing mechanisms associated with fibromyalgia. Cerephex is actively working towards obtaining FDA approval for NeuroPoint, enabling its use in clinical outpatient settings under physician supervision. Founded in 2012 and based in Los Altos, California, Cerephex was previously known as Great Lakes BioSciences.

Rox Medical

Series D in 2012
ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

ForSight VISION5

Venture Round in 2012
ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in developing innovative drug delivery technologies aimed at treating various eye conditions. The company focuses on creating non-invasive products designed to replace traditional eye drops, offering sustained therapy for significant eye diseases such as glaucoma, dry eye, and allergies. Currently, ForSight VISION5 is in its second Phase 2 clinical study for its lead product, the Helios insert, which represents a significant advancement in ocular treatment options.

AlterG

Series C in 2012
AlterG, Inc. is a manufacturer and distributor of rehabilitation and therapy equipment, headquartered in Fremont, California. The company specializes in developing innovative devices, most notably the Anti-Gravity Treadmill, which utilizes pressure-unweighting technology to facilitate physical therapy for individuals recovering from lower extremity injuries or surgeries. AlterG also offers the Stride Smart Gait Analytics treadmill, designed to enhance the benefits of anti-gravity therapy, and the AlterG Digital Video Monitoring System, which fosters collaboration between patients and therapists to optimize rehabilitation outcomes. Additionally, the company provides various accessories such as standard and performance shorts, as well as mats, to complement its rehabilitation equipment. Founded in 2004, AlterG aims to empower individuals to achieve their physical goals by improving mobility, reducing pain, and accelerating recovery times.

Halscion

Debt Financing in 2012
Halscion, Inc. is focused on developing innovative hydrogel scaffolds designed to enhance wound healing and improve scar outcomes. The company produces single-use hydrogel scaffold devices that are injected during surgical procedures at the dermal-subdermal interface of wounds. These biocompatible materials create a structural framework that facilitates the migration and organization of the patient's own healing cells, such as fibroblasts, into the wound. This technology aims to prevent or minimize scar formation, including conditions like keloid and hypertrophic scars. Established in 2005, Halscion is headquartered in Suwanee, Georgia.

NeoVista

Venture Round in 2012
NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.